Henry S. Friedman, MD

home / authors / henry-s-friedman-md

Articles

Vaccine Therapy, Oncolytic Viruses, and Gliomas

Annick Desjardins, MD;Gordana Vlahovic, MD;Henry S. Friedman, MD

March 16th 2016

In this article, we will discuss some of the vaccination and oncolytic virus strategies being evaluated in the clinic for malignant gliomas. The vaccines reviewed here include the cell-based and the non–cell-based.

Recent Advances in the Treatment of Pediatric Brain Tumors

Sri Gururangan, MRCP;Henry S. Friedman, MD

November 1st 2004

Central nervous system (CNS) cancers are the second most frequent malignancy in childhood. In recent years, significant advances in surgery, radiotherapy, and chemotherapy have improved survival in children with these tumors. However, a significant proportion of patients with CNS tumors suffer progressive disease despite such treatment.

Extending Principles Learned in Model Systems to Clinical Trials Design

Peter J. Houghton, PhD;Joyce Thompson, MD;Victor M. Santana, MD;Wayne L. Furman, MD;Henry S. Friedman, MD

August 1st 1998

Clinical results with irinotecan (CPT-11 [Camptosar]) and other camptothecin derivatives in various cancers, although encouraging, have fallen short of the expectations predicted by preclinical models. One proposed